Background: Bacteraemias caused by MSSA are associated with significant morbidity and mortality. Controversy exists over the optimal treatment of severe infections caused by MSSA. This systematic review and meta-analysis aims to identify whether differences in clinical outcomes exist between cefazolin and antistaphylococcal penicillins (ASPs).
Introduction
Staphylococcus aureus is among the most commonly identified pathogens in patients with bacteraemias.
1,2 Although MRSA is often of principal concern, MSSA remains prevalent and is associated with significant morbidity and mortality.
1,3 First-line treatment for serious MSSA infections (e.g. bacteraemia) is b-lactam therapy; namely, the antistaphylococcal penicillins (ASPs) (e.g. nafcillin, oxacillin), and the first-generation cephalosporin, cefazolin. Clinical treatment guidelines endorsed by the Infectious Diseases Society of America generally favour ASPs, with cefazolin recommended as an alternative agent (in the absence of CNS involvement). [4] [5] [6] Both ASPs and cefazolin are highly active in vitro against MSSA and used regularly for these infections in clinical practice. [4] [5] [6] [7] However, identification of an optimal treatment approach is critical given the substantial risk of bacteraemia-related complications. 2 Several retrospective studies of patients with serious MSSA infections have compared clinical outcomes between ASPs and cefazolin, though they have largely been unable to identify differences. [8] [9] [10] [11] [12] [13] [14] Optimal treatment for complicated patients with deep-seated infections such as endocarditis and osteomyelitis is of particular concern and remains controversial. [15] [16] [17] Some clinicians may select an ASP for deep-seated infections based on concerns of an inoculum effect observed with cefazolin in vitro. [18] [19] [20] MICs of cefazolin for MSSA have been shown to increase in certain isolates producing type A b-lactamases with higher bacterial inocula. [21] [22] [23] This phenomenon is not observed with ASPs in those same strains. While deep-seated infections may be associated with higher inocula, the clinical relevance of this in vitro finding is not well elucidated. 16, [19] [20] [21] 24, 25 Alternatively, clinicians may prefer cefazolin in certain scenarios given its improved tolerability, more convenient dosing (e.g. for patients receiving intermittent haemodialysis) and lower cost. 26, 27 Both ASPs and cefazolin have demonstrated effectiveness for patients with MSSA bacteraemia, and several individual studies have not identified a consensus option resulting in improved outcomes. Given the morbidity and mortality associated with serious MSSA infections and the potential for adverse drug effects in the setting of prolonged treatment durations, it is prudent to identify an optimal treatment, should one exist. 7 The purpose of this study was to compare both clinical effectiveness and safety outcomes associated with cefazolin compared with ASPs for the treatment of MSSA bacteraemias.
Methods

Search strategy
A systematic review of the literature was conducted within PubMed/ MEDLINE, Embase and the Cochrane Central Registry of Controlled trials for all publications from inception up to the end of November 2017. Search terms included 'cefazolin', 'nafcillin', 'oxacillin', 'cloxacillin', 'methicillin-susceptible Staphylococcus aureus', 'bacteraemia' and 'bloodstream infection'. Results were limited to full-text articles available in English. References of retrieved articles were also reviewed and assessed for possible inclusion.
Inclusion criteria
Studies were included per the following criteria: (i) hospitalized patients with MSSA bacteraemias received definitive treatment with either cefazolin or an ASP; (ii) clinical trial, cohort, or case-control study design; (iii) reported the primary endpoint for each treatment group (i.e. 90 day mortality); 28 and (iv) adult population. Articles were excluded if outcomes were not reported, outcome data were not readily extractable for each treatment group, or if the article was not available in English. Each article was evaluated independently for inclusion by two reviewers (J. N. O. and N. P.), with discrepancies resolved by a third (M. R. B.).
Data extraction
Data were extracted from included studies independently by two authors (J. N. O. and N. P.) and were standardized using a data extraction table.
Variables of interest included number of patients included in each group, duration of treatment, severity of illness measures, study design and source of infection.
Outcomes
The primary outcome of this meta-analysis was 90 day mortality. Secondary outcomes included 30 day mortality, clinical failure, discontinuations due to adverse effects and infection recurrence, as defined per each individual study.
Risk of bias
Risk of bias was evaluated independently by two reviewers (M. R. B. and N. P.) using the Newcastle-Ottawa Assessment Scale. 29 This scale was developed for evaluating non-randomized trials and assesses potential for bias within the categories of selection, comparability and outcome assessments. A third reviewer (J. N. O.) adjudicated unresolved discrepancies in risk of bias evaluations.
Statistical analysis
Meta-analyses were performed using Review Manager version 5.3 (Copenhagen, Denmark). Odds ratios and 95% CIs were calculated for dichotomous data. Statistical heterogeneity among studies was assessed using the v 2 statistic, with the I 2 statistic assessing the extent. 30 A MantelHaenszel random effects model was used for all analyses, as included studies were non-randomized and are known to be inherently heterogeneous. 31 
Results
Literature searches identified 704 studies (469 PubMed, 203 Embase, 32 Cochrane database) for evaluation. Exclusion of duplicate articles (n " 81) and non-English publications (n " 24) left 599 articles for review. Of these, seven met the criteria for inclusion in the meta-analysis. No additional studies were identified upon review of reference lists from the included studies (Figure 1) .
Characteristics of the seven studies are included in Table 1 . 8, [10] [11] [12] 20, 32, 33 All but one 20 were retrospective observational studies, and three used propensity score matching. 10, 12, 20 In total, 1589 and 2802 patients were treated with cefazolin or an ASP (i.e. cloxacillin, oxacillin or nafcillin), respectively, for MSSA bacteraemia. A summary of clinically relevant patient population characteristics in the included studies is shown in Table 2 . The percentage of patients admitted to an intensive care unit at the time of culture ranged from 10.8% (10 of 93) to 17.6% (556 of 3167) for the four studies that provided treatment-specific information. 8, 12, 32, 33 Reporting of illness severity was heterogeneous across studies given the variety of available classifiers.
Source of infection and presence of metastatic complications data were extractable for all but two studies, accounting for a total of 922 patients (Table 2) . 8, 10, 12, 20, 32 Bone, joint or musculoskeletal sources were the most common foci of infection (21.6%, 199); other reported sources in select studies were skin/soft tissue (17.9%, 165), catheter (13.9%, 128), respiratory (11.3%, 104), infective endocarditis (8.5%, 78) and other endovascular (6.0%, 20 of 362). 20, 32 Source of infection was unknown in 26.0% (240) of cases. Metastatic complications were reported in 24.6% of patients (227) who received ASPs or cefazolin.
Five studies assessed treatment failure. 8, 10, 20, 32, 33 Independent predictors of treatment failure in individual studies included duration of bacteraemia, metastatic complications including presence of endocarditis and severe illness, 10, 20, 32 whereas 90 day mortality predictors included age, liver cirrhosis and hospital-acquired bacteraemia.
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Mortality
Three of the seven studies used national registry databases to verify death. 11, 12, 33 Mortality occurred within 90 days in 18.2% (289 of 1589) of cefazolin-and 25.1% (703 of 2802) of ASP-treated patients. A statistically significant decrease in mortality was identified between patients receiving cefazolin compared with ASPs (OR 0.63, 95% CI 0.41-0.99, P " 0.05; Figure 2 ). Heterogeneity across studies was moderate (I 2 " 58%). A sensitivity analysis was conducted to evaluate the influence of the study by McDanel et al., 33 as it represented the majority of our total population. Removal of this study only affected the precision of the point estimate and associated 95% CI (OR 0.49, 95% CI 0.23-1.04, P " 0.05, I
2 " 65%). Four studies also reported 30 day mortality. 10, 20, 32, 33 Among these studies, cefazolin was associated with a significantly decreased odds of mortality relative to ASPs, with no heterogeneity across studies (OR 0.58, 95% CI 0.46-0.77, P , 0.001, I
2 " 0%,) (Figure S1 available as Supplementary data at JAC Online). The point estimate was heavily influenced by the inclusion of results published by McDanel et al. 33 (weight 96.3%). However, sensitivity analyses confirmed similar results without the inclusion of that study (OR 0.30, 95% CI 0.09-0.98, P " 0.05, I
2 " 0%).
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Clinical failure
Five of the seven studies evaluated clinical treatment failure. 8, 10, 20, 32, 33 Definitions varied by study, but included outcomes such as persistent bacteraemia, change of therapy due to lack of effectiveness, evidence of metastatic complications, and relapse or recurrence (Table 1) . Overall, 4.8% (70 of 1447) and 5.5% (136 of 2491) of patients treated with cefazolin or an ASP, respectively, experienced clinical failure. No significant decrease in the odds of clinical failure was observed in patients treated with cefazolin compared those treated with an ASP (OR 0.85, 95% CI 0.41-1.76, P " 0.66; Figure 3 ). Moderate heterogeneity was noted (I 2 " 74%).
Infectious recurrence
Five studies assessed reinfection, recurrence or relapse with cefazolin or ASPs within 90 days. 8, 10, 20, 32, 33 All included studies considered these outcomes to be a new MSSA infection following treatment of the index event, despite differences in terminology (Table 1 ). For simplicity we selected 'recurrence' as the singular term for these outcomes. No differences in rates of recurrence were observed between treatment groups with no heterogeneity (OR 1.28, 95% CI 0.68-2.40, P " 0.45, I
2 " 16%; Figure S2 ).
Discontinuation due to adverse effects
Few studies evaluated tolerability of either treatment. 10, 20, 32 In the three studies that reported tolerability data, cefazolin was associated with significantly fewer discontinuations due to adverse effects with no heterogeneity (OR 0.25, 95% CI 0.11-0.56, P , 0.01, I
2 " 13%; Figure 4 ).
Study risk of bias
Interrater agreement was 100% (M. R. B. and N. P.). The median Newcastle-Ottawa score for included studies was 8 (range 8-9) ( Table S1 ). The most common risk for bias was lack of adequate follow-up, as only three studies used national registries to verify mortality.
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Discussion
Clinical controversy exists surrounding the optimal agent for treatment of serious MSSA bacteraemias. [15] [16] [17] 19 In this meta-analysis of patients with MSSA bacteraemia, a statistically significant difference in 90 day mortality was identified between patients treated with cefazolin versus an ASP (95% CI 0.41-0.99). However, it is important to note that precision may be an issue as the upper bound of the CI approached the null value. Therefore, interpretation of this result should account for this. There was no difference between treatments in risk of recurrence within 90 days (P " 0.45). Significantly fewer patients discontinued cefazolin due to adverse effects (P , 0.01), though these data were infrequently reported. Optimal MSSA bacteraemia treatment JAC Bidell et al. 
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It is important to consider our findings in the context of potential predictors of the outcomes of interest. With respect to foci of infection, there was a higher proportion of patients who received cefazolin who had a catheter source [16.0% (58 of 362) versus 9.6% (54 of 560)] and fewer had a respiratory source [7.5% (27 of 362) versus 13.8% (77 of 560)] compared with those who received an ASP. One study 8 found neither catheter nor respiratory source to be significantly associated with 90 day mortality upon multivariate analysis; however, Lee et al. 10 found pneumonia to be significantly associated with treatment failure. Predictors of 90 day mortality in the included studies included age, liver cirrhosis and hospital-acquired bacteraemia. 8, 11 With respect to treatment failure, deep-seated infection including infective endocarditis and metastatic infection were significant predictors in multiple studies. 10, 20 Notably, these characteristics appeared similar between treatment groups across the meta-analysis population.
Source control is critical to effective treatment, particularly in severe infections such as MSSA bacteraemia. Treatment groupspecific source control data were only reported for three of the seven studies in this meta-analysis. 8, 10, 32 Pooling of these three studies revealed comparable rates of source control for cefazolin [41.4% (48 of 116)] compared with ASPs [42.0% (71 of 169)]; however, data were unavailable for the majority of the meta-analysis population, limiting interpretation. Test for overall effect: Z = 3.38 (P = 0.0007) Figure 4 . Forest plot of ORs for discontinuation due to adverse effects.
Optimal MSSA bacteraemia treatment JAC A limitation of many studies conducted previously is the small sample size, which may prevent detection of outcome differences between groups. The largest study in this meta-analysis was by McDanel et al., 33 comprising 72% (3436 of 4749) of the pooled population. This was a retrospective study comprised of patients from 119 Veterans Affairs hospitals between 2003 and 2010. After adjusting for confounding variables (i.e. diabetes, APACHE III 34, admission to ICU, and diagnosis of infective endocarditis), cefazolin was associated with a 23% decrease in 90 day mortality (adjusted HR 0.77, 95% CI 0.66-0.90) and 37% decrease in 30 day mortality compared with an ASP (adjusted HR 0.63, 95% CI 0.51-0.78). This is consistent with the findings of our meta-analysis, and sensitivity analyses showed that removal of this study resulted in minimal changes in point estimates for 30 and 90 day mortality. Unfortunately, data on source control and antibiotic dosing were not reported for the study population.
Our findings demonstrate a significant difference in 30 and 90 day mortality between cefazolin and ASPs for serious MSSA infections. These data contrast concerns regarding an inoculum effect described with cefazolin in preclinical studies, leading some clinicians to prefer ASPs for the treatment of MSSA bacteraemias. This effect has been well described in vitro in isolates expressing a Type A blaZ gene. [21] [22] [23] However, several considerations hinder the ability to draw definitive conclusions on the clinical relevance of this phenomenon. Firstly, blaZ may be affected by the bacterial growth phase, and associated b-lactamases exhibit variable affinities for cefazolin. 22 Secondly, in vitro studies do not capture the impact of the human immune response, nor the impact of drug re-dosing that is employed in clinical practice. 19 Thirdly, the prevalence of blaZ and the inoculum effect appears to vary widely. 24, [34] [35] [36] A multicentre study from the Chicago area found ,2% of MSSA isolates exhibited a cefazolin inoculum effect leading to resistant MICs, 23 while a single centre study from Atlanta showed a higher rate of cefazolin inoculum effect at 17%. 21 Several studies attempting to characterize the clinical relevance of this finding report inconsistent results. 20, 21, 24, 25 It may be of value to evaluate this at an institutional level. If concerns exist regarding use of cefazolin in the setting of high inoculum infection with concurrent concerns for ASP toxicity, clinicians may consider sequential therapy, starting with ASPs followed by cefazolin after the initial decrease in the inoculum. 15 Of note, this stepwise approach was not evaluated in the studies included in this meta-analysis.
In the absence of a clear clinical benefit with one agent, it is important to consider drug tolerability. Our findings of improved tolerability with cefazolin over ASPs is consistent with similar literature not included in these analyses. Recently, Flynt et al. 26 compared rates of acute kidney injury in patients receiving cefazolin or nafcillin for MSSA bacteraemias. They identified a significant increase in risk with patients receiving nafcillin, after controlling for ICU admission and endocarditis (OR 2.74, 95% CI 1.1-6.6). Youngster et al. 27 also identified significant tolerability issues with nafcillin compared with cefazolin in outpatients, with increased rates of rash (13.9 versus 4.2%, P , 0.01), renal dysfunction (11.4 versus 3.3%, P , 0.01), liver function abnormalities (8.1 versus 1.6%, P " 0.01) and early discontinuation of antibiotics (33.8 versus 6.7%, P , 0.01).
There are a number of limitations that should be considered when interpreting the findings of this analysis. Conclusions were derived from retrospective studies, which are inherently subject to bias. While the majority of studies were found to have limited risk of bias using the Newcastle-Ottawa scoring system, use of ASPs in patients deemed to be clinically 'sicker' or having a deep-seated infection must be considered. Though we believe our findings to be of clinical value, there is risk that these may be over-generalized, given that important predictors of outcomes were not consistently evaluated or reported across studies. Important missing data include MIC information, time to clearance of blood cultures, time to appropriate therapy, antibiotic dosing strategies and prevalence of blaZ/inoculum effect. Furthermore, severity of illness scoring (e.g. APACHE II, SOFA, Pitt Bacteremia Score) and adjusted odds of mortality were not consistently reported across all studies, limiting adjustment for these effects on mortality. Source control data were also reported inconsistently. While patients with complicated bacteraemias and deep-seated infections were included in all studies, the representation within each study population varied substantially. The utilization of Mantel-Haenszel random effects models result in a more conservative estimate of effects and a bias towards the null, but is appropriate when included studies are uncontrolled since inherent bias exists within these study designs. 31 This approach also may have low power to detect differences when heterogeneity is high and number of included studies is low. Only studies published in English were included, which may affect the precision of the point estimates. Furthermore, the definition of treatment failure varied by study (Table 1) . Clinicians would benefit from the creation of standardized definitions in future treatment guidelines.
In conclusion, this meta-analysis identified a significant decrease in 90 day mortality between cefazolin and ASPs for the treatment of MSSA bacteraemia. Additionally, cefazolin appeared to be better tolerated than ASPs in these patients. It is important to note that adjustment for confounders was limited by the extractable data reported in each study. The prevalence of MSSA exhibiting a cefazolin inoculum effect is likely variable and should be considered at the individual level. While differences in specific outcomes (i.e. 90 day mortality and discontinuation due to adverse events) were observed between cefazolin and ASPs in uncontrolled studies, it is important for clinicians to consider patient-specific factors when selecting antimicrobial treatment for patients with invasive MSSA infections.
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